Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin - Wikidata - awgldk - TriplyDB

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

http://www.wikidata.org/entity/Q33367978

about

Heparin-induced thrombocytopenia in the ICU: an overview Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients HITlights: a career perspective on heparin-induced thrombocytopenia Atomic description of the immune complex involved in heparin-induced thrombocytopenia A multistate model for bivariate interval-censored failure time data.Heparin-induced thrombocytopenia and cardiovascular patients: recognition and treatment.The management of heparin-induced thrombocytopenia.Beyond heparin and warfarin: the new generation of anticoagulants.Heparin-induced thrombocytopenia: treatment options and special considerations.Testing for heparin-induced thrombocytopenia: are we there yet?Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?Determinants of PF4/heparin immunogenicity Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes Current concepts review: heparin-induced thrombocytopenia.Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis.Fondaparinux: does it cause HIT? Can it treat HIT?IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics.Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach HIT paradigms and paradoxes.Immunogenic but effective: the HIT-fondaparinux brain puzzler.Fondaparinux-associated heparin-induced thrombocytopenia Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH)Management of heparin-induced thrombocytopenia.The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE).Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.The incidence, causes, and prognostic significance of new-onset thrombocytopenia in intensive care units: a prospective cohort study in a Korean hospital.Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis.Heparin-induced thrombocytopenia following hip and knee arthroplasty.Heparin-induced thrombocytopenia leading to stroke, lower extremity arterial occlusive disease, and skin necrosis: a case report.Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.Efficacy and safety of off-label use of fondaparinux in the management of heparin-induced thrombocytopenia with thrombosis in an elderly woman.

P2860

Q21194907-85935F40-0E54-4BB6-8DD2-43CD7E20C178 Q24200589-51A6E5E0-1145-405E-B097-82699F8E3F50 Q26828351-F2A3E540-2EA6-4FEC-A7A6-BD26A4F2FAD9 Q30665349-25D95CAD-6FE3-4D2B-9B1E-CFA5D01FE582 Q31143773-5F6E5465-1C2F-4701-9C43-AB3BEDFAB2C7 Q33370473-407004E4-2AF6-432B-A685-CABDA52AE53E Q33371013-FE29786B-7C48-4EC0-80F0-E9EDCCC2F098 Q33374258-BBADD9C3-8B20-43DD-90F0-90B8AE2166A6 Q33374658-2A9A3012-1A19-45CC-868B-01BCFF2E9AD2 Q33374916-79DA97F1-801E-49A7-981E-34DAE5F27A0C Q33376013-F31D0728-1801-4B89-AAEF-470B2E172ACF Q33376629-04410F2E-EF88-4AB3-9648-A6BA342780D1 Q33380179-65039339-9010-4592-86CF-7666E74CA248 Q33381352-FF4C612D-1511-4C90-AC95-898E712F5F28 Q33382108-25400FF8-6A25-4C7F-A9C3-666F149E5BC3 Q33384243-1EEE127D-738F-4947-84EB-A5A8FD29F5CB Q33386621-CBB355DA-9B6A-40A8-8D32-E731FA818313 Q33387713-A711CD07-2145-45C5-8A8A-20CEE6397A03 Q33389966-52284517-3312-435B-9E36-4794484DE191 Q33392854-F7284914-7A97-400E-BAD9-235FA9610A45 Q33392864-FEB4E365-EF54-4457-B726-2754D40C114C Q33393788-66EBE1F8-778E-49A4-8158-94978F00DCCD Q33394988-C02C5130-5519-4565-AE8C-5D7FDBFE1FC2 Q33396243-F17829E6-314C-4CF3-96A8-2022DCBDA8F2 Q33396313-F291B87E-D86D-4478-BA75-9F608AD7EC34 Q33397282-82E70E0C-632D-4DFE-B2A0-C11D8F0EFAAF Q33399335-96134591-37CA-4503-8763-A58DABC341D2 Q33399576-3C37050E-F9CF-48F2-8B6D-A09681665E5D Q33399613-3E2020D3-7FA5-403F-8828-76A2FC7F386C Q33400573-DD0149D2-3BE7-4F0A-990E-89914E12B5B9 Q33401236-CC7E3FEF-74A0-46B1-A315-A2D4886BBF3A Q33402370-3F3B6D1D-BF0D-4E17-95C0-F67E8089EE7B Q33403703-FDC59E0E-87E1-46AE-865B-30E376A64C7B Q33404467-7B4ADBCB-5148-45CF-98CD-64E14918F5A6 Q33404709-406BB92F-70F7-40B7-A120-1E79738DD843 Q33405846-575AB233-1AC3-4868-BBE4-25874877D602 Q33406618-6CBDD7E7-CA60-4B5B-AD1A-0F5F6FCE61C7 Q33406904-096D8B74-5B8D-448C-9432-4E6AB510292E Q33407198-B5899916-E092-49B5-93DF-814EE3C3449F Q33408949-65D5EB5A-12B5-453E-A3BD-4D3226BEB42B

P2860

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

http://www.wikidata.org/entity/Q33367978

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin

@ast

Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin

@en

type

label

Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin

@ast

Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin

@en

prefLabel

Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin

@ast

Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin

@en

P1433

Q33367978-4F950A55-26F1-4F48-8D6C-C94317C18845

P1476

Q33367978-EFE3E4B9-52E8-4701-8968-FC51747719D6

P2093

Q33367978-6E89228F-8FB3-4AF8-A2AB-26F8611680F2

Q33367978-86ED8320-375A-41DE-BDE7-393EBD14A9FB

Q33367978-A428901D-CAD0-4505-912B-6DFAA2795595

Q33367978-DB6080C6-0722-4648-8E11-EC8DF5658A18

Q33367978-E3ADE483-ABA0-415E-BDF2-B808E273E289

Q33367978-FC97D628-F75B-4A7B-A207-A717BD009AE4

P2860

Q33367978-00041CAA-4448-4E22-8EDA-C5BB4D2CDAB2

Q33367978-007C5978-88A5-4FED-AAC3-E51744C9A652

Q33367978-07D5F4D3-A242-448A-8B1A-D3CEBBD0DA9B

Q33367978-0D987C90-2257-4D6D-882C-9D19D3FC2816

Q33367978-0F14FB3C-E2CA-4F89-A62A-C9CDE2CA84B5

Q33367978-1763BC47-2A29-46DB-886F-D9452BED5926

Q33367978-1EA05735-5FFA-4DA0-AB64-27E154908505

Q33367978-30A50416-9963-482B-8E50-8D7469A37E08

Q33367978-3654CB82-A71A-4793-BE8E-39B671B17CD7

Q33367978-3B8364D0-7497-4CB8-A8EA-0BD5D347B4AF

P304

Q33367978-FE52E37D-F954-439B-AC95-A47FB57158CF

P31

Q33367978-0E130FF1-A7D3-4C17-8C12-F005D91D4661

P356

Q33367978-C2CE20DB-0C60-4CAB-AA90-5118E7CA33AC

P407

Q33367978-7A78B566-F817-45EB-BF04-991E3ABF7297

P433

Q33367978-F1548771-2494-48AD-A24D-4B3A5940924C

P478

Q33367978-019EBCD0-8403-40CC-ACF9-FC5823C394C3

P50

Q33367978-7F5D2563-E623-4E34-A894-9F617072ECB9

Q33367978-820E3FE7-4643-4F82-96B1-DDE51DAEADFA

P577

Q33367978-568ECCE1-9C51-4C57-ACA2-4E2CE7CB47AA

P5875

Q33367978-5AC7C6B8-796B-4ECE-A1C5-0EAB2B526F1E

P698

Q33367978-468276BA-F024-4622-96BA-F90F4524264C

P921

Q33367978-ED37D819-562A-43E4-8129-07B09E0652BD

P932

Q33367978-C02D232A-5811-4D60-9518-083ECA026CCA

P356

BLOOD-2005-05-1938

P1433

P1476

Anti-platelet factor 4/heparin ...... ith fondaparinux or enoxaparin

@en

P2093

Bengt I Eriksson

http://www.w3.org/2001/XMLSchema#string

Jane C Moore

http://www.w3.org/2001/XMLSchema#string

Jo-Ann I Sheppard

http://www.w3.org/2001/XMLSchema#string

John G Kelton

http://www.w3.org/2001/XMLSchema#string

Richard J Cook

http://www.w3.org/2001/XMLSchema#string

Victor J Marder

http://www.w3.org/2001/XMLSchema#string

P2860

Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.

Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis.

Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia.

Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.

Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.

Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.

Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance.

Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.

Heparin-associated thrombocytopenia: the antibody is not heparin specific.

P304

3791-3796

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-05-1938

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Theodore E Warkentin

Andreas Greinacher

P577

2005-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7650550

http://www.w3.org/2001/XMLSchema#string

P698

16109780

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895104

http://www.w3.org/2001/XMLSchema#string